Zentalis Pharmaceuticals (ZNTL) Depreciation & Amortization (CF) (2019 - 2026)

Zentalis Pharmaceuticals' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $151000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 42.37% year-over-year to $151000.0 in Q1 2026; TTM through Mar 2026 was $589000.0, a 52.0% decrease from a year earlier, with the FY2025 full-year figure at $700000.0, down 45.69% from the prior year.
• Depreciation & Amortization (CF) climbed to $151000.0 in Q1 2026 per ZNTL's latest filing, from $118000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $375000.0 in Q3 2022 and bottomed at $118000.0 in Q4 2025.
• The 5-year median for Depreciation & Amortization (CF) is $321000.0 (2024), against an average of $285823.5.
• Across the five-year window, Depreciation & Amortization (CF) soared 335.44% in 2022 and slumped 62.78% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $300000.0 in 2022, then changed by 0.0% to $300000.0 in 2023, then gained by 5.67% to $317000.0 in 2024, then slumped by 62.78% to $118000.0 in 2025, then grew by 27.97% to $151000.0 in 2026.
• Per Business Quant, the three latest ZNTL Depreciation & Amortization (CF) figures stand at $151000.0 (Q1 2026), $118000.0 (Q4 2025), and $160000.0 (Q3 2025).